Evidence map›Paper›PMID 38372523›Full record

ArticleLa Tunisie medicale2023

Sihem Mensi, Abir Ezzine, Teheni Dardouri, Mohamed Ben Rejeb, Maha Ben Fredj, Kaouther Chatti

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in La Tunisie medicale, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sihem MensiNuclear Medicine Department, Sahloul Hospital, Sousse, Tunisia.
Abir EzzineNuclear Medicine Department, Sahloul Hospital, Sousse, Tunisia.
Teheni DardouriNuclear Medicine Department, Sahloul Hospital, Sousse, Tunisia.
Mohamed Ben RejebResearch Laboratory "LR12ES03", Department of Family and Community Medicine, Ibn El Jazzar Sousse Faculty of Medicine, University of Sousse, Tunisia.
Maha Ben FredjNuclear Medicine Department, Sahloul Hospital, Sousse, Tunisia.
Kaouther ChattiNuclear Medicine Department, Sahloul Hospital, Sousse, Tunisia.
Hôpital Sahloul · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDifferentiated thyroid cancer (DTC), despite its good prognosis, affects the quality of life (QOL) of patients by its physical and psychological repercussions and by the toxicity of treatment. A study of the quality of life as well as the potentially associated factors is necessary in order to carry out targeted actions.

aimThis work was conducted to assess the quality of life of patients treated for thyroid cancer.

methods89 patients treated surgically and by iratherapy for DTC responded from January 2018 to December 2019 to the SF36 questionnaire in its validated version in Tunisian dialect. A descriptive and bivariate analysis between the scores of the different domains and the variables of interest was performed.

resultsThe overall mean score (SMG) of the QOL of our patients ranged from 12.8 to 94.25 with a mean of 58±22%. The factors that proved to have a positive impact on the QOL of patients followed for CDT assessed by the SMG and/or the mental summary score (MSS) and/or the physical summary score (PSS) were: male gender (p=0.034), higher educational level (p=0.037), early TNM stage (p=0.041) and low cumulative iodine-131 dose (≤ 5550 MBq) (p=0.031).

conclusionQOL is strongly influenced by many sociodemographic and clinical factors. More attention should be paid to patients followed for DTC to improve quality of life.

Indexed as

AdenocarcinomaThyroid NeoplasmsHumansMaleQuality of LifeSurveys and Questionnaires

Identifiers

PMID38372523
PMCPMC11361298
OpenAlexW4394739395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.